Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure

11 Jun, 2021

Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure
Photo by Hunters Race on Unsplash

– Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.
– New investors are UTokyo Innovation Platform Co. (UTokyo IPC), Medical Incubator Japan, Keio Innovation Initiative (KII), and Sumitomo Mitsui Trust Investment. Among the existing investors, SBI Group, Nissay Capital, SMBC Capital, Medipal Holdings, and Itochu Chemical Frontier participated in this round.

Eastern Asia Health Care
Crunchbase icon

Content report

The following text will be sent to our editors: